Published in

Nature Research, Nature, 7417(489), p. 519-525, 2012

DOI: 10.1038/nature11404

Elsevier, Year Book of Pathology and Laboratory Medicine, (2013), p. 290-291

DOI: 10.1016/j.ypat.2012.11.048

Links

Tools

Export citation

Search in Google Scholar

Comprehensive genomic characterization of squamous cell lung cancers

Journal article published in 2012 by Jianhua Zhang, Jinhua Zhang, Nianxiang Zhang, Yiqun Zhang, Spring Yingchun Liu, Jianjua John Zhang, Douglas Voet, Petar Stojanov, Andrey Sivachenko, Yongjun Zhao, Thomas Zeng, Peter S. Hammerman, Carrie Sougnez, Nam H. Pho, Erin Pleasance and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Lung squamous cell carcinoma is a common type of lung cancer, causing approximately 400,000 deaths per year worldwide. Genomic alterations in squamous cell lung cancers have not been comprehensively characterized, and no molecularly targeted agents have been specifically developed for its treatment. As part of The Cancer Genome Atlas, here we profile 178 lung squamous cell carcinomas to provide a comprehensive landscape of genomic and epigenomic alterations. We show that the tumour type is characterized by complex genomic alterations, with a mean of 360 exonic mutations, 165 genomic rearrangements, and 323 segments of copy number alteration per tumour. We find statistically recurrent mutations in 11 genes, including mutation of TP53 in nearly all specimens. Previously unreported loss-of-function mutations are seen in the HLA-A class I major histocompatibility gene. Significantly altered pathways included NFE2L2 and KEAP1 in 34%, squamous differentiation genes in 44%, phosphatidylinositol-3-OH kinase pathway genes in 47%, and CDKN2A and RB1 in 72% of tumours. We identified a potential therapeutic target in most tumours, offering new avenues of investigation for the treatment of squamous cell lung cancers.